IN THIS ISSUE
The US opioids crisis was a key talking point in 2019. With high-profile legal battles putting the pharma industry under a spotlight, the ongoing fallout from the scandal has left a deep dent in both the finances and reputations of many pharma companies. But how will the industry address the epidemic moving forward? We find out.
Plus, we examine two concepts that could bridge the gap between precision medicine and blanket drug development, take a look at the first recyclable unit dose packaging, and explore the benefits of Trikafta, the world’s first triple combination therapy for cystic fibrosis.
Also, we find out about innovation in the cannabinoid industry, talk to Cidara about resistance to anti-fungal medications, investigate pharma’s attitude to whistleblowers and data leaks, and find out what is causing medication shortages around the world.
Eloise McLennan, editor